Median Amphiregulin levels were significantly higher than found in the cancer-free controls in the Cohort 1 ER + patients (P = 0.0068) and in the Cohort 2 ER + patients (P = 0.019) suggesting a shift towards Amphiregulin positivity in women with breast cancer. Here, ESR1 is linked to breast carcinoma.